Ryan Notti (left) and Thomas Walz (right) discovered new characteristics of a T cell receptor that are essential to a variety ...

A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric ...

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company ...

CAR T-cell therapy can be a lifesaving treatment for blood cancers like leukemia and lymphoma. The gene therapy trains a patient’s T cells—white blood cells that play an important role in the immune ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...